IND-Enabling Development of Rx100 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome.

NIH RePORTER · NIH · N01 · $1,524,658 · view on reporter.nih.gov ↗

Abstract

This contract supports the development of safe and effective MCMs to mitigate and/or treat tissue injuries arising from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading to a reduction in radiation-associated morbidities and mortalities.

Key facts

NIH application ID: 10241884
Project number: 272201800052C-P00009-9999-1
Recipient: RXBIO, INC.
Principal Investigator: SHANNON MCCOOL
Activity code: N01
Funding institute: NIH
Fiscal year: 2020
Award amount: $1,524,658
Award type: —
Project period: 2018-09-01 → 2021-08-31